Reta glucagon-like peptide-1 (GLP-1) receptor agonists represent a groundbreaking method to diabetes management. These innovative medications function by mimicking the natural actions of GLP-1, a hormone produced by the gut in response to consumption. By activating GLP-1 receptors in the pancreas, these compounds increase insulin release and inhibi

The burgeoning landscape of novel treatments for body management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a similar therapeutic goal – improving glycemic control and promoting considerable weight reduction – they exhibit intriguing differences in their ph